Tumor Response by Immune-Related Adverse Event Occurrence
| Best Responsea | irAE, n = 130 pts | No irAE, n = 1405 pts |
|---|---|---|
| Complete Response (CR) | 8 (6.2%) | 67 (4.8%) |
| Partial Response (PR) | 37 (28.5%) | 239 (17%) |
| Stable Disease (SD) | 48 (37%) | 483 (34.4%) |
| Progressive Disease | 32 (25%) | 470 (33.5%) |
| Missing | 5 (3.8%) | 146 (10.4%) |
| CR + PR + SD (n, %) | 93 (71%) | 789 (56%)bp = 0.0008 |
| CR + PR (n, %) | 45 (34.6%) | 306 (21.8%)cp = 0.0014 |
irAE immune-related adverse event; pts.-patients;
aBest response is determined from responses captured between baseline IL-2 administration and prior to subsequent treatment
bFisher’s exact test comparing CR + PR + SD by irAE to no irAE
cFisher’s exact test comparing best response by irAE to no irAE